ENLV
Enlivex Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.11
−4.31%Next report
Analyst consensus
- Next report date
- Sep 4, 2026
- EPS estimate
- -$0.31
- Revenue estimate
- —
Latest reported
- Last report date
- Sep 4, 2026
- EPS actual
- -$0.31
- EPS estimate
- -$0.31
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -147.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $80
- PT range
- $80 – $80
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 7, 2026